PolyMedix Inc. (PYMX) announced that the United States Adopted Names or USAN Council, in consultation with the World Health Organization or WHO International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "brilacidin" (pronounced bri-la-ci-din) for PMX-30063, a first-in-class defensin mimetic antibiotic.
PolyMedix said it recently announced positive results from a Phase 2 clinical study with brilacidin as an intravenous treatment in patients with acute bacterial skin and skin structure Staph aureus infections.
The company said that the USAN Council has also approved the use of the nonproprietary generic name "delparantag" (pronounced del-par-an-tag) for PMX-60056, PolyMedix's first-in-class anticoagulant reversing agent.
Click here to receive FREE breaking news email alerts for PolyMedix Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com